Psicofarmaci e farmaci antiretrovirali

Translated title of the contribution: Psycotropic and antiretroviral drugs

E. Seminari, A. Sforzini, P. Villani, F. Barale, R. Maserati

Research output: Contribution to journalArticlepeer-review

Abstract

Psychiatric comorbidity is common in HIV/AIDS patients and psychiatric disorders are found in a number of individuals, significantly higher than what is to be expected in the general population. The majority of psychotropic drugs interacts with antiretroviral drugs because of the common matabolization pathway in the liver's cytochrome P450 system. The use of tricyclic antidepressant with protease inhibitors may require dose reduction while serotonine selective reuptake inhibitors are better tolerated. Long half-life benzodiazepines as midazolam and triazolam may raise severe side effects, therefore other molecules with shorter half-life should be preferred. The use of antipsychotic drugs is associated to the tendency of HIV-positive patients to exhibit adverse affects, therefore the best course is to start with low doses and increase the dosage slowly and progressively. The association of antipsychotic drugs requires caution because of the increase in plasma concentrations of neuroleptics.

Translated title of the contributionPsycotropic and antiretroviral drugs
Original languageItalian
Pages (from-to)145-151
Number of pages7
JournalGiornale Italiano di Malattie Infettive
Volume5
Issue number3
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Psycotropic and antiretroviral drugs'. Together they form a unique fingerprint.

Cite this